3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
2
Unknown
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Hepatocellular
27
Parkinson Disease 4, Autosomal Dominant Lewy Body
24
Neoplasms
14
Melanoma
9
Endometrial Neoplasms
8
Carcinoma, Renal Cell
7
Carcinoma, Non-Small-Cell Lung
7
Thyroid Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Cholangiocarcinoma
6
Stomach Neoplasms
4
Recurrence
4
Carcinoma
4
Biliary Tract Neoplasms
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Lymphoma
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Paraganglioma, Extra-Adrenal
2
Osteosarcoma
2
Neuroendocrine Tumors
2
Lung Neoplasms
2
Liver Neoplasms
2
Glioma
2
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid cancer, Hurthle cell
1
Interventions
Carboplatin
49
Etoposide
46
Cisplatin
42
Topotecan
39
Irinotecan
21
Paclitaxel
20
Nivolumab
15
pembrolizumab
13
Gemcitabine
13
atezolizumab
11
Ipilimumab
11
durvalumab
9
Radiotherapy
9
Doxorubicin
7
Bevacizumab
7
rovalpituzumab tesirine
6
etoposide phosphate
6
amrubicin
6
Psychiatric Rehabilitation
6
PM 01183
6
Docetaxel
6
Counseling
6
trilaciclib
5
Temozolomide
5
Sunitinib
5
Platinum
5
Imatinib Mesylate
5
Cyclophosphamide
5
Bortezomib
5
130-nm albumin-bound paclitaxel
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Small Cell Lung Carcinoma
×
lenvatinib
×
Clear all
NCT04924101
2025-07-23
KEYNOTE-B99
Merck Sharp & Dohme LLC
Phase 2
Completed
126 enrolled